F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

Fiche publication

Date publication

décembre 2025

Journal

Breast cancer research : BCR

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOURAHLA Khalil , Pr PETIT Thierry

Tous les auteurs :
Chanchou M, Mouret-Reynier MA, Molnar I, Deshayes E, D'Hondt V, Bourahla K, Petit T, Bardet S, Levy C, Morel O, Augereau P, Rousseau C, Campone M, Monteil J, Venat-Bouvet L, Faye A, Benavent V, Cachin F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41339898

Résumé

F-FDG PET-CT has emerged as a powerful imaging tool for initial staging and prognosis evaluation of patients with Breast Cancer (BC). However, previous studies are inconsistent on attributing a predictive value to the pathological Complete Response (pCR) determined by PET-CT. Our objective was to assess the association between pCR and F-FDG PET-CT findings in patients with HER2+ BC in neoadjuvant setting.